CHMP recommends granting marketing authorisation to Raxone for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Posted: 26 June 2015 |
CHMP has recommended granting marketing authorisation to Raxone for the treatment of visual impairment in patients with Leber’s Hereditary Optic Neuropathy…
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for Santhera’s Raxone (idebenone) for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON).
LHON is a heritable mitochondrial disease that leads to rapid, profound and usually permanent blindness in otherwise healthy patients. Raxone will be the first treatment option for LHON and the first approved therapy for a mitochondrial disease.
“This is a major breakthrough as it paves the way for the first medicinal product to become available for the treatment of a mitochondrial disease,” stated Thomas Klopstock, MD (Professor for Neurology at the University of Munich, LHON investigator and coordinator of the German network for mitochondrial disorders, mitoNET). “LHON is a severe form of vision loss caused by mitochondrial dysfunction. Affected patients, usually young and otherwise healthy, rapidly lose central vision and become bilaterally blind within a few months from the onset of symptoms. Although there is a chance for partial or even full spontaneous recovery, most patients remain permanently blind if untreated. The mode of action of idebenone provides a clear biochemical and medical rationale and the clinical data demonstrate that vision of affected patients can substantially improve upon treatment with Raxone. This recommendation is a landmark in mitochondrial disease research worldwide and will undoubtedly spur further research in this direction.”
If approved, Raxone will be the first treatment option for LHON
“We are very excited about the CHMP’s positive opinion, which recognises the urgent medical need for a treatment for this devastating disease,” stated Thomas Meier, PhD, CEO of Santhera. “We can now execute on our plans to ensure Raxone is made available to patients in the EU as soon as the European Commission marketing authorization is received.”
The CHMP based its recommendation for Raxone on data from the randomised, placebo controlled RHODOS trial, Santhera’s Expanded Access Programme, and comparative natural history data from a comprehensive case record survey. The Committee considered that the totality of the data provided for an orphan disease as severe as LHON with no available treatment options warranted a recommendation for approval under Exceptional Circumstances. Santhera has undertaken to gather additional long-term efficacy and safety data in LHON patients as post-authorsation measures.
The positive opinion by the CHMP for Raxone will now be forwarded to the European Commission (EC) for the adoption of a decision on EU-wide marketing authorisation, applicable to all 28 member states of the European Union as well as Iceland, Liechtenstein and Norway. Raxone has orphan designation which provides 10 years of market exclusivity from the date of EC approval.